Cost-effectiveness analysis of a new paradigm to simplify testing, monitoring and treatment of hepatitis C virus in the United States

被引：0

作者：

Dietrich, Douglas ^{[1
]}

Reau, Nancy ^{[2
]}

Ahmed, Aijaz ^{[3
]}

Blissett, Rob ^{[4
]}

Igloi-Nagy, Adam ^{[4
]}

Yehoshua, Alon ^{[5
]}

机构：

[1] Mt Sinai Hlth Syst, Inst Liver Med, New York, NY USA

[2] Rush Univ, Dept Hepatol, Med Ctr, Chicago, IL USA

[3] Stanford Univ, Div Gastroenterol & Hepatol, Sch Med, Stanford, CA USA

[4] Maple Hlth Grp LLC, New York, NY 10019 USA

[5] Gilead Sci, Foster City, CA USA

来源：

COST EFFECTIVENESS AND RESOURCE ALLOCATION | 2025年 / 23卷 / 01期

关键词：

Hepatitis C virus; Cost-utility model; Testing and treatment; United States; SINGLE-ARM; OPEN-LABEL; PHASE; 4; INFECTION;

D O I：

10.1186/s12962-025-00622-y

中图分类号：

R19 [保健组织与事业（卫生事业管理）];

学科分类号：

摘要：

The hepatitis C virus (HCV) testing and treatment pathway in the United States (US) includes a range of tests and appointments causing delays and loss to follow-up. We assessed the cost-effectiveness of simplifying the pathway using an economic model to estimate health outcomes, cost differences and incremental cost per quality-adjusted life year (QALY) and life year (LY) of the new paradigm compared to the other scenarios. The analysis compared three scenarios, one based on treatment guidelines, one based on real-world practice and a hypothetical scenario with a simplified pathway ("new paradigm"); these differed in testing and treatment process steps and times. The new paradigm resulted in cost reductions between $19,751 and $16,448, and excess QALYs between 0.42 and 0.70, suggesting that simplifying the US HCV patient pathway may be cost-effective and allows a quicker path to successful treatment and reduce the number of patients lost to follow-up.

引用

页数：8

共 21 条

[1]

( AASLD) IDSoAIAAftSoLD, 2022, HCV Guidance: Recommendations for Testing, Managing and Treating Hepatitis V. 2022 Update

[2]

Cartwright EJ, 2023, MMWR Morbidity and Mortality Weekly Report, P72

[3] Early treatment of acute or recently acquired hepatitis C: An important tool on the path to HCV elimination! [J].

Cornberg, Markus ;

Wedemeyer, Heiner .

HEPATOLOGY, 2025, 81 (03) :771-773

[4] COVID-19 and addiction [J].

Dubey, Mahua Jana ;

Ghosh, Ritwik ;

Chatterjee, Subham ;

Biswas, Payel ;

Chatterjee, Subhankar ;

Dubey, Souvik .

DIABETES & METABOLIC SYNDROME-CLINICAL RESEARCH & REVIEWS, 2020, 14 (05) :817-823

[5] Rapid Treatment Initiation for Hepatitis C in Young People Who Inject Drugs: The Seek, Test, and Rapid Treatment Randomized Trial [J].

Eckhardt, Benjamin ;

Kapadia, Shashi N. ;

Mateu-Gelabert, Pedro ;

Pai, Melinda ;

Fong, Chunki ;

Aponte-Melendez, Yesenia ;

Marks, Kristen M. .

OPEN FORUM INFECTIOUS DISEASES, 2022, 9 (07)

[6] Clinical and economic benefits of a new paradigm of HCV diagnosis and treatment [J].

Fagiuoli, Stefano ;

Ruggeri, Matteo ;

Aragao, Filipa ;

Blissett, Rob .

GLOBAL & REGIONAL HEALTH TECHNOLOGY ASSESSMENT, 2021, 8 :58-66

[7] The Hepatitis C Care Cascade During the Direct-Acting Antiviral Era in a United States Commercially Insured Population [J].

Ferrante, Nicole D. ;

Newcomb, Craig W. ;

Forde, Kimberly A. ;

Leonard, Charles E. ;

Torgersen, Jessie ;

Linas, Benjamin P. ;

Rowan, Sarah E. ;

Wyles, David L. ;

Kostman, Jay ;

Trooskin, Stacey B. ;

Lo Re, Vincent .

OPEN FORUM INFECTIOUS DISEASES, 2022, 9 (09)

[8] Hepatitis C virus and hepatocellular carcinoma: carcinogenesis in the era of direct-acting antivirals [J].

Fiehn, Felix ;

Beisel, Claudia ;

Binder, Marco .

CURRENT OPINION IN VIROLOGY, 2024, 67

[9]

Finbrten A-K., 2022, Gastroenterol Hepatol, V18, P629

[10] The Impact of COVID-19 on Syringe Services Programs in the United States [J].

Glick, Sara N. ;

Prohaska, Stephanie M. ;

LaKosky, Paul A. ;

Juarez, Alexa M. ;

Corcorran, Maria A. ;

Des Jarlais, Don C. .

AIDS AND BEHAVIOR, 2020, 24 (09) :2466-2468

← 1 2 3 →